Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

Core Insights - Disc Medicine, Inc. is set to present clinical data on DISC-0974 at the 2024 ASN Kidney Week, focusing on its Phase 1b study in patients with non-dialysis dependent chronic kidney disease and anemia [1][2] - The study aims to evaluate safety and changes in hepcidin, iron levels, and hematologic parameters [1][2] Presentation Details - The presentation will include data from the 40mg and 60mg dose cohorts, covering safety, pharmacokinetics, and effects on hepcidin and anemia [2][3] - The abstract for the presentation is available on the ASN Kidney Week conference website [2] Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for serious hematologic diseases, focusing on red blood cell biology and iron homeostasis [4]